In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria
Antimicrobial resistance is a global health problem. In 2021, it was estimated almost half a million of multidrug-resistant tuberculosis (MDR-TB) cases. Besides, non-tuberculous mycobacteria (NTM) are highly resistant to several drugs and the emergence of fluoroquinolone (FQ) resistant M. tuberculos...
| Main Authors: | , , , , |
|---|---|
| Format: | Artículo |
| Language: | Inglés |
| Published: |
Japan Antibiotics Research Association
2024
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.12123/18738 https://www.nature.com/articles/s41429-024-00709-3 https://doi.org/10.1038/s41429-024-00709-3 |
| _version_ | 1855486232296947712 |
|---|---|
| author | Imperiale, Belen Rocio Mancino, María Belén Moyano, Roberto Damian de la Barrera, Silvia Morcillo, Nora |
| author_browse | Imperiale, Belen Rocio Mancino, María Belén Morcillo, Nora Moyano, Roberto Damian de la Barrera, Silvia |
| author_facet | Imperiale, Belen Rocio Mancino, María Belén Moyano, Roberto Damian de la Barrera, Silvia Morcillo, Nora |
| author_sort | Imperiale, Belen Rocio |
| collection | INTA Digital |
| description | Antimicrobial resistance is a global health problem. In 2021, it was estimated almost half a million of multidrug-resistant tuberculosis (MDR-TB) cases. Besides, non-tuberculous mycobacteria (NTM) are highly resistant to several drugs and the emergence of fluoroquinolone (FQ) resistant M. tuberculosis (Mtb) is also a global concern making treatments difficult and with variable outcome. The aim of this study was to evaluate the activity of the FQ, DC-159a, against Mtb and NTM and to explore the cross-resistance with the currently used FQs. A total of 12 pre-extensively drug-resistant (XDR) Mtb, 2 XDR, 36 fully drug susceptible strains and 41 NTM isolates were included to estimate the in vitro activity of DC-159a, moxifloxacin (MOX) and levofloxacin (LX), using minimal inhibitory and bactericidal concentration (MIC and MBC). The activity inside the human macrophages and pulmonary epithelial cells were also determined.
DC-159a was active in vitro and ex vivo against mycobacteria. Besides, it was more active than MOX/LX. Moreover, no cross-resistance was evidenced between DC-159a and LX/MOX as DC-159a could inhibit Mtb and MAC strains that were already resistant to LX/MOX.
DC-159a could be a possible candidate in new therapeutic regimens for MDR/ XDR-TB and mycobacterioses cases. |
| format | Artículo |
| id | INTA18738 |
| institution | Instituto Nacional de Tecnología Agropecuaria (INTA -Argentina) |
| language | Inglés |
| publishDate | 2024 |
| publishDateRange | 2024 |
| publishDateSort | 2024 |
| publisher | Japan Antibiotics Research Association |
| publisherStr | Japan Antibiotics Research Association |
| record_format | dspace |
| spelling | INTA187382024-08-01T10:14:36Z In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria Imperiale, Belen Rocio Mancino, María Belén Moyano, Roberto Damian de la Barrera, Silvia Morcillo, Nora Antibiotics Tuberculosis Mycobacterium Antimicrobial Resistance Antibiótico Resistencia a los Antimicrobianos Antimicrobial resistance is a global health problem. In 2021, it was estimated almost half a million of multidrug-resistant tuberculosis (MDR-TB) cases. Besides, non-tuberculous mycobacteria (NTM) are highly resistant to several drugs and the emergence of fluoroquinolone (FQ) resistant M. tuberculosis (Mtb) is also a global concern making treatments difficult and with variable outcome. The aim of this study was to evaluate the activity of the FQ, DC-159a, against Mtb and NTM and to explore the cross-resistance with the currently used FQs. A total of 12 pre-extensively drug-resistant (XDR) Mtb, 2 XDR, 36 fully drug susceptible strains and 41 NTM isolates were included to estimate the in vitro activity of DC-159a, moxifloxacin (MOX) and levofloxacin (LX), using minimal inhibitory and bactericidal concentration (MIC and MBC). The activity inside the human macrophages and pulmonary epithelial cells were also determined. DC-159a was active in vitro and ex vivo against mycobacteria. Besides, it was more active than MOX/LX. Moreover, no cross-resistance was evidenced between DC-159a and LX/MOX as DC-159a could inhibit Mtb and MAC strains that were already resistant to LX/MOX. DC-159a could be a possible candidate in new therapeutic regimens for MDR/ XDR-TB and mycobacterioses cases. Instituto de Biotecnología Fil: Imperiale, Belen Rocio. Academia Nacional de Medicina. Instituto de Medicina Experimental (IMEX); Argentina Fil: Imperiale, Belen Rocio. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Mancino, María Belén. Hospital Dr. Antonio A. Cetrángolo. Laboratorio de Referencia del Programa de Control de la Tuberculosis de la provincia de Buenos Aires; Argentina Fil: Moyano, Roberto Damian. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina Fil: Moyano, Roberto Damian. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: de la Barrera, Silvia. Academia Nacional de Medicina. Instituto de Medicina Experimental (IMEX); Argentina Fil: de la Barrera, Silvia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Morcillo, Nora. Hospital Dr. Antonio A. Cetrángolo. Laboratorio de Referencia del Programa de Control de la Tuberculosis de la provincia de Buenos Aires; Argentina 2024-08-01T10:06:25Z 2024-08-01T10:06:25Z 2024-05 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/20.500.12123/18738 https://www.nature.com/articles/s41429-024-00709-3 1881-1469 https://doi.org/10.1038/s41429-024-00709-3 eng info:eu-repo/semantics/restrictedAccess http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) application/pdf Japan Antibiotics Research Association The Journal of Antibiotics 77 (5) : 306-314 (May 2024) |
| spellingShingle | Antibiotics Tuberculosis Mycobacterium Antimicrobial Resistance Antibiótico Resistencia a los Antimicrobianos Imperiale, Belen Rocio Mancino, María Belén Moyano, Roberto Damian de la Barrera, Silvia Morcillo, Nora In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria |
| title | In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria |
| title_full | In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria |
| title_fullStr | In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria |
| title_full_unstemmed | In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria |
| title_short | In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria |
| title_sort | in vitro and ex vivo activity of the fluoroquinolone dc 159a against mycobacteria |
| topic | Antibiotics Tuberculosis Mycobacterium Antimicrobial Resistance Antibiótico Resistencia a los Antimicrobianos |
| url | http://hdl.handle.net/20.500.12123/18738 https://www.nature.com/articles/s41429-024-00709-3 https://doi.org/10.1038/s41429-024-00709-3 |
| work_keys_str_mv | AT imperialebelenrocio invitroandexvivoactivityofthefluoroquinolonedc159aagainstmycobacteria AT mancinomariabelen invitroandexvivoactivityofthefluoroquinolonedc159aagainstmycobacteria AT moyanorobertodamian invitroandexvivoactivityofthefluoroquinolonedc159aagainstmycobacteria AT delabarrerasilvia invitroandexvivoactivityofthefluoroquinolonedc159aagainstmycobacteria AT morcillonora invitroandexvivoactivityofthefluoroquinolonedc159aagainstmycobacteria |